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PURPOSE. To provide a clinical and genetic description of a patient cohort with Stargardt
disease (STGD1) with identifiable foveal sparing.
METHODS. Patients with retinal atrophy (defined as an absence of autofluorescence) that
surrounded the fovea by at least 1808 and did not include the fovea were defined as having
foveal sparing; eyes with visual acuity (VA) worse than 20/200 were excluded. We reviewed
the medical files and extracted data regarding medical history, VA, ophthalmoscopy, static
perimetry, fundus photography, spectral-domain optical coherence tomography (SD-OCT),
fluorescein angiography (FA), fundus autofluorescence (FAF), and electroretinography (ERG).
We screened each patient’s ABCA4 gene for mutations.
RESULTS. Seventeen eyes with foveal sparing were identified in 13 unrelated patients. In 4 eyes,
the fovea gradually became atrophic after the initial foveal sparing. The mean age at onset was
51 years (range, 32–67 years). Visual acuity was 20/40 or better in all foveal sparing eyes and
was 20/25 or better in 41%. Fundus autofluorescence imaging revealed hyperautofluorescent
flecks and parafoveal retinal atrophy; SD-OCT revealed sharply delineated atrophy; and
perimetry revealed parafoveal scotomas with intact foveal sensitivity. Finally, genetic
screening identified mutations in 19 of the 26 ABCA4 gene alleles.
CONCLUSIONS. Foveal sparing occurs mainly in patients with late-onset STGD1 and represents
the milder end of the clinical spectrum in STGD1. The anatomy, metabolism, and
biochemistry of the retina, as well as genetic variations in genes other than ABCA4, can
influence the etiology of foveal sparing. Identifying these fovea-protecting factors will
facilitate the future development of strategies designed to treat STGD1.
Keywords: foveal sparing, Stargardt disease, ABCA4
Within the retina, the macula provides the highest visualacuity and contains the highest density of cones.1,2
Therefore, a loss of central vision is a hallmark feature of
macular dystrophies. There are, however, exceptions to this
rule. Foveal sparing is an intriguing phenomenon in which
retinal atrophy surrounds a relatively preserved fovea, leaving
central visual acuity largely unaffected. Although foveal sparing
has been reported in a variety of conditions, including Stargardt
disease (STGD1),3–5 mitochondrial retinal dystrophy associated
with the m.3243A>G mutation,6 and geographic atrophy in
age-related macular degeneration (AMD),7–11 its etiology
remains poorly understood.
Stargardt disease is an autosomal recessive retinal dystrophy
that typically presents within the first two decades of life.12
Although the clinical presentation of STGD1 varies widely, it is
usually characterized by a progressive loss of central vision,
irregular yellow-white fundus flecks, and the so-called beaten
bronze atrophic macular lesions.13–15 Stargardt disease has
been linked to mutations in the ABCA4 gene, which encodes an
adenosine triphosphate (ATP)-binding cassette transporter
(ABCR) expressed specifically in the cones and rods of the
retina.16,17 Defects in ABCR function cause the accumulation of
all-trans-retinal and its cytotoxic derivatives (e.g., diretinoid-
pyridinium-ethanolamine) in photoreceptors and retinal pig-
ment epithelial (RPE) cells, ultimately causing RPE cell death
and the subsequent loss of photoreceptors.18
Mutations in ABCA4 have been linked to a spectrum of
phenotypes ranging from mild macular dystrophy to severe
early-onset panretinal dystrophy.3,19–22 We previously postulat-
ed that disease severity may be correlated with the functional
severity of the particular mutation in the resulting ABCR
protein.19,23–25 The substantial clinical variability among
patients with STGD1—including an age at onset of the
symptoms that can range from 5 to 72 years of age, diverse
fundoscopic features, diverse electrophysiological findings, and
a variable time course of vision loss—suggests the presence of
several strong modifying factors.3,13,14
Recently, Fujinami et al.26 reported the clinical and
molecular genetic findings of a cohort of STGD1 patients with
relatively preserved foveal structure and function (based on
seemingly normal autofluorescence at the fovea). Their study
revealed the presence of two basic—yet distinct—STGD1
phenotypes, namely STGD1 patients with foveal sparing and
STGD1 patients with early-onset foveal atrophy.26 However, the
onset of foveal involvement in STGD1 can vary substantially
and can occur in later disease stages, for example, in late-onset
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STGD1.3 This heterogeneity complicates the selection of
homogeneous cohorts for clinical studies to investigate the
subtype of STGD1 patients with foveal sparing.
Here, we report the clinical characteristics and the natural
course of foveal sparing in a cohort of STGD1 patients with
foveal sparing, and we explore the mechanisms that may
underlie this phenomenon.
METHODS
Patients and Genetic Analysis
The patient selection process is depicted in Figure 1. The
database of the Department of Ophthalmology at Radboud
University Medical Center (Nijmegen, The Netherlands)
contains 425 clinically suspected cases of STGD1. For 257 of
these patients, an ABCA4 genetic screen for known mutations
was performed in the Department of Human Genetics at
Radboud University Medical Center using arrayed primer
extension analysis (APEX) microarrays (Asper Biotech, Tartu,
Estonia). Because STGD1 is autosomal recessive, if the Asper
microarray screen revealed only one mutation in a given
patient, we sequenced the exons and intron–exon boundaries
in ABCA4 to identify the mutation in the second allele. All
mutations were confirmed using Sanger sequencing. The
presence of one or two mutations in the ABCA4 gene
confirmed the diagnosis of STGD1 in 198 patients. For our
study, we selected cases in which foveal sparing was
documented using fundus photography and/or fundus auto-
fluorescence (FAF) imaging. Patients with RPE atrophy
(defined as an absence of autofluorescence surrounding the
fovea by least 1808) that did not include the fovea were defined
as having foveal sparing. Eyes with visual acuity of 20/200 or
worse were presumed to have little or no foveal function and
were therefore excluded. Twelve unrelated STGD1 patients
with foveal sparing in at least one eye were included in this
study. We also included one additional patient who initially
presented with foveal sparing; in this patient, the fovea became
atrophic as the disease progressed. To exclude pseudo-
Stargardt pattern dystrophy,27 the PRPH2 gene was sequenced
in all 13 patients.
This study was performed in accordance with the tenets of
the Declaration of Helsinki, and all participating patients gave
their informed consent prior to providing a blood sample and
receiving additional ophthalmologic examinations.
Clinical Examination
Clinical data were collected from the medical records of the 13
eligible patients. The data collected included the patient’s age
at onset, medical history, initial symptoms, and the overall
course of the retinal disorder. Age at onset was defined as the
age at which the initial symptoms were noted by the patient.
We defined the duration of symptomatic disease as the time
from the age at onset to the patient’s current age. In the
patients who were initially asymptomatic, the age at their first
visit to the ophthalmologist was used to define disease
duration.
The standard ophthalmic examination included a measure-
ment of best-corrected visual acuity (BCVA) using Snellen
visual acuity charts and ophthalmoscopy. The central visual
field was assessed with a Humphrey perimeter (Carl Zeiss
Meditec, Jena, Germany) using central 10-2, 24-2, or 30-2
threshold tests in two, two, and four patients, respectively.
Fundus photography (Topcon TRC50IX; Topcon Corporation,
Tokyo, Japan) was performed in 10 patients. Fluorescein
angiography (FA) was performed in 10 patients to screen for
the presence of the dark choroid sign. Full-field electroreti-
nography (ffERG; 8 patients) and multifocal ERG (mfERG; 7
patients) were performed using Dawson-Trick-Litzkow (DTL)
electrodes and the RETI-port system (Roland Consults, Stasche
& Finger GmbH, Brandenburg an der Havel, Germany). Both
the ffERG and mfERG recordings were performed in accor-
dance with the guidelines of the International Society for
Clinical Electrophysiology of Vision (ISCEV).28
Cross-sectional images were obtained using spectral-domain
optical coherence tomography (SD-OCT; Heidelberg Engineer-
ing, Heidelberg, Germany) in 12 patients; a 208 3 158 19-line
scan covering the fovea was used. Total retinal thickness, outer
nuclear layer (ONL) thickness, and photoreceptor–RPE
(PRþRPE) complex thickness were measured at the foveal
dip and at 0.25-, 0.5-, 1-, 1.5-, 2-, and 2.5-mm eccentric
distances using Heidelberg Eye Explorer software (Version
1.6.4.0; Heidelberg Engineering). Outer nuclear layer thickness
FIGURE 1. Flow chart depicting the selection process of Stargardt
patients with foveal sparing for inclusion in the study. FP, fundus
photography.
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was measured from the outer plexiform layer to the external
limiting membrane (ELM); PRþRPE thickness was measured
from the ELM to Bruch’s membrane; and total retinal thickness
was measured from the vitreous–retinal interface to RPE–
Bruch’s membrane complex. Clinically normal values for total
retinal thickness, ONL thickness, and PRþRPE thickness were
obtained from 25 age-matched individuals (mean age, 46 years;
range, 27–62 years) with no retinal or vitreoretinal disease; we
performed a postacquisition interpolation of the normal data
using custom programs (MatLab R2011a; The MathWorks, Inc.,
Natick, MA, USA).
We acquired FAF images using a confocal scanning laser
ophthalmoscope (cSLO; Spectralis; Heidelberg Engineering).
After the pupil was dilated, 308 and/or 558 field-of-view FAF
images were obtained from all patients (except case 11) using
an optically pumped solid-state laser with 488-nm excitation.
Two independent observers (RACvH and NMB) measured the
size of the atrophic lesions (determined using the absence of
autofluorescence) as described previously.29
RESULTS
Clinical Characteristics
Of the 198 patients with a confirmed diagnosis of STGD1, 13
unrelated patients (7%) had foveal sparing. The clinical
characteristics of these 13 patients (including all 26 eyes) are
summarized in Table 1. This cohort included five women and
eight men; all 13 patients were of Caucasian descent, with a
mean age at onset of 52 years (range, 32–67 years). The mean
disease duration was 9 years (range, 1–34 years). These
patients were diagnosed between the age of 39 and 82 years
(mean, 57 years). None of the patients were using hydroxy-
chloroquine at the time of the study, nor had they used this
drug in the past.
Foveal sparing was present in 17 of the 26 eyes (65%), and
five of the 13 patients (38%) had bilateral foveal sparing. In
seven of the patients with unilateral foveal sparing, five of the
contralateral eyes had no signs of RPE atrophy or parafoveal
atrophic RPE lesions that surrounded the fovea by less than
1808. In the remaining two eyes, and in both eyes in patient 12,
the fovea degenerated after initial foveal sparing (Table 1).
Nine of the 13 patients (69%) initially experienced a decline
in visual acuity. Other initial symptoms included paracentral
scotoma in four patients (31%), metamorphopsia in two
patients (15%), and nyctalopia in one patient (8%). Two
patients (patients 2 and 13; 15%) initially experienced no visual
complaints, but were referred to our department because of
fundus abnormalities found during ophthalmologic screening
for glaucoma or thyroid eye disease; after 9 and 6 years,
respectively, these two patients experienced a perceived
decrease in visual acuity (Table 1). The BCVA was 20/40 or
better in all 17 eyes with foveal sparing; seven of these 17 eyes
(41%) had a BCVA of 20/25 or better. In the four eyes in which
atrophy ultimately affected the fovea, BCVA had decreased to
20/200 from an initial acuity of 20/25 to 20/40 when the
fovea was spared.
In 12 patients, a fundus examination revealed irregular
flavimaculatus flecks scattered throughout the posterior pole
and occasionally extending anterior to the vascular arcades
(Figs. 2A, 2B, 3A). One patient had small perifoveal yellow-
white dots. Patient 12, who had bilateral foveal degeneration,
developed extensive chorioretinal atrophy of the posterior
pole and the midperiphery during the patient’s 26 years of
follow-up (Fig. 2C). Masking of the choroidal background
fluorescence (i.e., a so-called dark choroid) was evident on FA
imaging in seven patients, four of whom carried a single
heterozygous ABCA4 mutation (Tables 1, 2). The flavimacula-
tus flecks were visible as an irregular pattern of hyper-
fluorescence and hypofluorescence on FA imaging (Fig. 3B),
and they appeared as hyperautofluorescent flecks on FAF
imaging (Figs. 3C, 4). The chorioretinal atrophy corresponded
with sharply delineated areas that included both an absence of
autofluorescence and structural thinning of the outer retinal
layers on OCT (Fig. 3D). Static perimetry revealed sharply
delineated absolute parafoveal scotomas (Fig. 4) with subnor-
mal foveal sensitivity (median, 35 dB; range, 20–39 dB). Foveal
sensitivity was not measurable (<0 dB) in patient 12, which is
consistent with the anatomical findings and other functional
results obtained from this patient.
The results of the ffERG recordings in 10 eyes with foveal
sparing are summarized in Table 1. In these 10 eyes, photopic
amplitude was normal in seven eyes (70%) and moderately
reduced in three eyes (30%), and scotopic amplitude was
normal in eight eyes (80%) and moderately reduced in two eyes
(20%). In the four eyes that developed an atrophic fovea after
initial foveal sparing, the photopic and scotopic amplitudes
were either normal or severely reduced (Table 1). In three
patients (patient 5, right eye; patient 8, left eye; and patient 13,
left eye), the scotopic amplitude was reduced more markedly
than the amplitude of photopic flash responses, although none
of these patients had peripheral pigmentary retinopathy. No
clear correlation was found between ffERG response and
disease duration, visual acuity, or fundoscopic characteristics.
We also measured mfERG in eight eyes with foveal sparing and
found that the P1-response amplitudes in the central two rings
(representing the foveal retina) were relatively intact compared
to the outer three rings, which showed severely reduced
responses.
Retinal Structure
Spectral-domain OCT imaging was performed in 12 patients
and revealed highly localized damage to the lamellar architec-
ture of the macula. We observed parafoveal atrophy of
photoreceptors and RPE cells with sharp borders, represented
by a loss of the bands associated with the ELM, the ellipsoid
inner segments, and the RPE (Figs. 5B–5E).30 These bands were
present in the fovea, however, although many of the bands that
corresponded to the ELM and ellipsoid inner segments were
irregular. In addition, the longer outer segments—which are
characteristic of cone photoreceptors in the foveal dip—were
not observed in any of these 12 eyes (Figs. 5A–5D). In three
eyes, we observed signs reminiscent of outer retinal tubulation
at the border of the atrophic lesions (Fig. 5D), although no
rosette-like structures (as described by Zweifel and col-
leagues31) were observed. Microcystoid macular edema was
present in three eyes (Fig. 5C), and epiretinal gliosis with
retinal wrinkling extending over the fovea was observed in one
eye.
An analysis of the retinal lamellar architecture revealed that
the overall retinal thickness in the foveal and parafoveal
regions was generally decreased (Fig. 5F). The thickness of
both the ONL and PRþRPE layers was normal at the foveal
center in most patients. However, in the parafoveal region, the
PRþRPE was usually nearly absent, whereas the ONL was
progressively thinner in this region (Fig. 5F).
Natural Course of Foveal Sparing
An analysis of the longitudinal FAF data, which were available
for six patients, enabled us to investigate the natural course of
foveal sparing. In general, fundus flavimaculatus flecks were
observed in the early stages, in some cases even before
symptoms developed. Within one to two decades of diagnosis
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(range, 10–18 years), one or more sharply delineated
parafoveal RPE atrophic areas appeared (Fig. 4A). Over time,
these lesions expanded and reached confluence around the
fovea, thus producing the foveal sparing phenotype. We
observed three distinct stages in the development of foveal
sparing; these stages characterize the natural course of the
phenomenon. In stage 1, parafoveal atrophic lesions emerge,
with several intact RPE connections between the fovea and
the surrounding vital RPE (Figs. 4A, 4C). In stage 2, the
atrophic RPE lesions interconnect, leaving only a single
isthmus of RPE, thus resulting in a ‘‘peninsula-like’’ appear-
ance (Figs. 4E. 4G). Stage 3 is characterized by an isolated
fovea that is surrounded completely by RPE atrophy (Figs. 4I,
4K). We measured the expansion rate of the atrophic lesions
in four patients using the FAF follow-up data (Table 3). The
rate of expansion ranged from 0.832 to 2.363 mm2/y in these
patients, and the rate was positively correlated to the size of
the atrophic lesions. Given this wide range of expansion rates,
it is unclear how long foveal sparing is present before the
foveal structure and function become significantly affected by
the profound atrophy; however, we observed that the foveal
structure and function were relatively preserved for up to 6
FIGURE 2. Fundus photographs of three patients with STGD1. (A) Fundus photograph of the right eye of patient 4 (at age 60), showing fundus
flavimaculatus flecks and parafoveal atrophy of the RPE. (B) Fundus photograph of the left eye of case 5 (at age 45), showing fundus flavimaculatus
flecks and parafoveal atrophy of the RPE. (C) Mosaic of fundus photographs of the right eye of case 12 (at age 73), showing profound central
atrophy of the RPE; this patient previously had foveal sparing.
FIGURE 3. Multimodal imaging of the right fundus of patient 3 at age 62. (A) Fundus photograph showing irregular flavimaculatus flecks and
atrophy of the central RPE; note that the fovea is spared. (B) Fluorescein angiograph showing the dark choroid sign, hyperfluorescence, visible
choroidal vessels due to window defects, and a normal-appearing fovea. (C) Fundus autofluorescence image showing hyperautofluorescent flecks
and RPE atrophy with foveal sparing. The green horizontal line indicates the scanning level of the OCT scan in (D). (D) An OCT scan through the
fovea clearly shows the preserved cone photoreceptors in the fovea surrounded by atrophy of the outer retina and RPE.
Foveal Sparing in Stargardt Disease IOVS j November 2014 j Vol. 55 j No. 11 j 7472
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933042/ on 05/08/2017
years in patients 8 and 12. Eventually, the remaining foveal
tissue became progressively smaller, and atrophy of the
central fovea was observed in four eyes (in patients 10, 11,
and 12; Figs. 4L, 4N, 5E); this was accompanied by a decline
in central vision to 20/200 or worse.
Genetic Analysis and Mutation Screening
An examination of the pedigrees of the 13 unrelated patients
with foveal sparing revealed a recessive inheritance pattern in
five patients; the other eight patients appeared to be isolated
cases. Mutations in the ABCA4 gene were identified in 19 of
the 26 alleles (73%, Table 2). We identified compound
heterozygous mutations in six patients (46%) and single
heterozygous mutations in the other seven patients (54%). In
total, 13 different ABCA4 variants were identified, including
nine missense mutations, two splice site mutations, one
nonsense mutation, and one synonymous variant that affects
splicing.23 Each of these variants has been described previously
(Table 2).
The mutational effects of five of the identified mutations
have been reported previously (Supplementary Table S1).
Although functional data regarding the effects of the other
eight mutations is not available, we can speculate on the
functional effect of the nonsense mutation (p.Gln1292*).
Assuming that the resulting mRNA is not subject to non-
sense-mediated decay, the resulting truncated protein will lack
the second extracytoplasmic domain and the nucleotide-
binding domain, which are involved in substrate and ATP
binding, respectively.32 Supplementary Table S2 summarizes
the identified missense mutations in ABCA4, including allele
frequencies in the exome variant server (EVS) and scores
obtained from selected predictive tools. No differences in
phenotype were observed between patients carrying severe
mutations and patients carrying mild mutations. Finally, no
pathogenic mutations in the PRPH2 gene were identified in
this cohort, thereby excluding the possibility of pseudo-
Stargardt pattern dystrophy.27
DISCUSSION
Here, we present the clinical characteristics of 13 STGD1
patients with foveal sparing in one or both eyes. The majority
of these patients were diagnosed with late-onset STGD1; only 3
patients developed symptoms prior to the age of 45 (Table 1).
In eyes with foveal sparing, visual acuity was relatively
preserved; nevertheless, most of the patients experienced
some loss of vision, which caused them to seek ophthalmo-
logic care. In these instances, ophthalmoscopy readily revealed
advanced retinal disease, with yellow-white irregular pisciform
flecks and profound RPE atrophy adjacent to the fovea.
Automated perimetry revealed perifoveal scotomas of various
sizes with intact foveal sensibility. This combination of mild
vision loss together with profound retinal abnormalities is
typical among STGD1 patients with foveal sparing.
Recently, Fujinami et al.26 reported the clinical and
molecular findings of a cohort of Stargardt patients with a
foveal sparing phenotype. In their study, the authors included
STGD1 patients with a functional fovea, irrespective of the
presence of parafoveal RPE atrophy; thus, they studied a
heterogeneous cohort of 40 patients. In contrast, in our cohort
we defined foveal sparing as profound RPE atrophy that
surrounded the fovea by at least 1808 and spared the fovea’s
structure and function. This clinical presentation is a rare
finding among STGD1 patients, and our strict selection
criterion resulted in a small but homogeneous cohort with a
consistent phenotype and excluded STGD1 patients with late-
onset disease that began with foveal atrophy. Moreover, our
definition of foveal sparing is consistent with previously
reported cases of foveal sparing in patients with other
degenerative diseases.6,8,33,34 Despite the differences between
our cohort and the cohort described by Fujinami et al.,26 the
visual acuity and electrophysiology findings in their paper are
similar to the findings in our study; nevertheless, none of our
patients were carriers of the ABCA4 p.Arg2030Gln missense
mutation, which was suggested previously to be prevalent
among STGD1 patients with foveal sparing.26
The Etiology of Foveal Sparing
In our study, screening the ABCA4 gene identified 19
pathogenic mutations that were described previously in
STGD1 and/or other ABCA4-associated retinopathies (Table
2)16,23,35–45; interestingly, however, foveal sparing was not
described in any of the patients who were previously reported
to carry these mutations. In a previously proposed model that
links phenotype severity to the degree of residual ABCR
function,23,24 late-onset STGD1 with foveal sparing was placed
at the mild end of the spectrum of ABCA4-associated
retinopathies.3 Indeed, none of our STGD1 patients with
foveal sparing had two ABCA4 variants that are associated with
TABLE 2. ABCA4 Mutations in STGD1 Patients With Foveal Sparing
Allele 1 Allele 2
ReferencesDNA Variant Effect DNA Variant Effect
P1 c.5461-10TC Unknown NI NA 35, 36
P2 c.3113CT p.Ala1038Val c.3874CT p.Gln1292* 16, 37, 38, 58
P3 c.5461-10TC Unknown c.5537TC p.Ile1846Thr 23, 35, 39, 58
P4 c.4363TC p.Cys1455Arg NI NA 40
P5 c.1822TA p.Phe608Ile c.4685TC p.Ile1562Thr 23, 40, 41, 59
P6 c.768GT Splice defect c.3113CT p.Ala1038Val 16, 23, 37
P7 c.5196þ1GT Splice defect NI NA 45, 58
P8 c.3874CT p.Gln1292* NI NA 38
P9 c.5461-10TC Unknown NI NA 35, 58
P10 c.1822TA p.Phe608Ile NI NA 23, 41
P11 c.286AG p.Asn96Asp NI NA 43
P12 c.1805GA p.Arg602Gln c.4462TC p.Cys1488Arg 37, 39, 42–44
P13 c.3874CT p.Gln1292* c.1928TG p.Val643Gly 38, 45
NI, not identified; NA, not applicable.
* Nonsense mutation.
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FIGURE 4. Natural course of fundus and perimetric changes in STGD1 with foveal sparing. FAF imaging can be used to identify the three stages that
occur in foveal sparing. In stage 1, confluent parafoveal RPE lesions surround the macula, leaving several connections of intact RPE with the
surrounding vital RPE (stage 1 [A, C]). Over time, the RPE atrophy progresses, and the lesions interconnect, leaving only one isthmus of RPE (stage 2
[E, G]). Further disease progression leads to an isolated fovea that is surrounded completely by RPE atrophy (stage 3 [I, K]). Eventually, RPE atrophy
overcomes foveal resistance, leading to foveal degeneration (post foveal sparing [L, N]). Static perimetry examination reveals absolute perifoveal
scotomas with intact foveal sensitivity in all eyes with foveal sparing (B, D, F, H, J). Large absolute scotomas with diminished foveal sensitivity were
observed in the eyes post foveal sparing (M, O). (A, B) FAF (A) and 24-2 perimetry (B) in patient 13 at age 63. (C, D) FAF (C) and 30-2 perimetry (D)
in patient 4 at age 60 and 61, respectively. (E, F) FAF (E) and 10-2 perimetry (F) in patient 3 at age 64 and 65, respectively. (G, H) FAF (G) and 24-2
perimetry (H) in patient 5 at age 45. (I, J) FAF (I) and 30-2 perimetry (J) in patient 8 at age 66 and 65, respectively. (K) FAF in patient 6 at age 58. (L,
M) FAF (L) and 30-2 perimetry (M) in patient 10 at age 53. (N, O) FAF (N) and 30-2 perimetry (O) in patient 12 at age 73.
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a severe loss of ABCR function. However, our knowledge
regarding the functional consequences of ABCA4 mutations
identified to date is limited (Supplementary Table S1). It can be
extremely difficult to assess the effect of most missense
variants using in silico predictions and allele frequencies in
healthy individuals, for whom this information is often
incomplete (Supplementary Table S2); in addition, assessing
the combined effect of carrying two ABCA4 variants is
FIGURE 5. OCT analysis of Stargardt patients with foveal sparing. (A–E) The structural aspects of the macula in a healthy individual ([A] age 51),
case 2 ([B] age 60), case 3 ([C] age 45), case 8 ([D] age 65), and case 10 ([E] age 53). The white arrows in (D) indicate the locations of signs
resembling outer retinal tubulation. The black arrowheads in (C, D, E) indicate the locations of abrupt photoreceptor layer disturbances without
gradual outer and/or inner segment loss. The white arrowhead in (C) indicates the presence of microcysts in the inner nuclear layer. (F) Summary
of thickness measurements of the total retina (top), ONL (middle), and PRþRPE (bottom). The gray shaded areas show the distribution (mean 6 2
SD) of the total retinal, ONL, and PRþRPE thickness in 25 age-matched healthy individuals (mean age, 46 years).
TABLE 3. Results of Progression Analysis on Fundus Autofluorescence Imaging During Follow-Up in STGD1 Patients With Foveal Sparing
ID
Age at Initial
Visit, y
Duration Follow-up
Eye
Atrophy at Initial
Visit, mm2*
Atrophy at
Follow-up, mm2*
Expansion During
Follow-up, mm2*
Progression Rate,
mm2/y*Days Years
P1 57 597 1.6 Right 3.517 4.877 1.36 0.832
P2 59 842 2.3 Right 11.792 15.770 3.978 1.726
Left 11.202 16.43 5.228 2.268
P8 63 1657 4.5 Right 16.308 27.027 10.719 2.363
P9 62 420 1.1 Right 3.570 4.601 1.031 0.897
* Measurements were performed by two authors (RACvH and NMB), and the average of the two measurements is shown. Mean interobserver
variance was 2.7% (range, 0.4%–9.8%).
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particularly difficult. Functional assays are needed in order to
form definitive conclusions regarding the effects of these
mutations.
Because foveal sparing can be present in phenotypes that
are independent of ABCA4 mutations, including AMD and
mitochondrial retinal dystrophy,6,8–12,17,20,25,44,45 genetic fac-
tors other than ABCA4 mutations are likely involved. These
factors could include single nucleotide polymorphisms (SNPs)
and even mutations in retina-specific genes other than ABCA4,
which suggests that a digenic or triallellic trait—in combina-
tion with the identified ABCA4 mutations—may underlie the
degenerative pattern observed in our patients. Moreover,
anatomical, metabolic, and/or biochemical factors may under-
lie foveal sparing. For example, the average peak density of
cones in the fovea is 199,000 cones/mm2, but can range from
98,200 to 324,100 cones/mm2.2 The initial number of cones in
the fovea may play a role in the development of foveal sparing;
however, adaptive optics imaging techniques—which can
provide the resolution needed to determine photoreceptor
density in vivo—are not generally available in most ophthal-
mology practices. Another factor to consider is that S (‘‘blue’’)
cone photoreceptors, which are absent in the foveal center,
seem to be more vulnerable to retinal disease than M and L
cones, although this selective vulnerability has not been
reported in STGD1.46,47 Moreover, parafoveal rods appear to
be more vulnerable than cones to the effects of aging and all-
trans-retinal–mediated damage.48–50 This difference may arise
from the sole dependence of rods on the RPE for replenishing
11-cis-retinal; in contrast, cones are also supplied by Mu¨ller
cells.51 Furthermore, cone cells have a slower turnover rate of
outer segments compared to rods,52 although this does not
necessarily result in higher all-trans-retinal levels in RPE cells,
as regeneration is faster in cones than in rods.51 Macular
pigments, which can filter out high-energy light, may also serve
a protective role, given that light exposure is crucial in the
pathogenesis of STGD1.53,54 In addition, rod-derived cone
viability factor (RdCVF), which is believed to prevent cone
degeneration,55 may also play a role. Importantly, the absolute
levels of macular pigments and RdCVF may differ between
STGD1 patients with foveal sparing and STGD1 patients
without foveal sparing.
Differential Diagnosis and Clinical Significance of
Foveal Sparing
When forming a diagnosis, foveal sparing–associated clinical
entities other than late-onset STGD should be considered,
including geographic atrophy in AMD, mitochondrial retinal
dystrophy associated with the m.3243A>G mutation, central
areolar choroidal dystrophy, and pseudo-Stargardt pattern
dystrophy.6,9,10,27,29 Importantly, misdiagnosing this condition
can lead to inappropriate genetic counseling (these diseases
display unique inheritance patterns) and/or an inaccurate
estimate of the prognosis. Furthermore, in the event of an
incorrect diagnosis of AMD, prescribing vitamin A–rich
nutritional supplements can accelerate the accumulation of
all-trans-retinal–derived toxins and increase the rate of disease
progression, as shown in the retinas of homozygous Abca4-
knockout mice.56 Stargardt disease with foveal sparing can be
diagnosed based on the presence of characteristic pisciform
flecks together with RPE atrophy surrounding the fovea, a
‘‘dark choroid’’ sign on FA, and genetic analysis of the ABCA4
gene. Fundus autofluorescence imaging can clearly highlight
the fundus flecks, which appear as hyperautofluorescent
flecks, and RPE atrophy, which appears as an absence of
autofluorescence. Retinal dystrophies that closely resemble
STGD1 can follow other patterns of inheritance—for example,
due to mutations in mitochondrial DNA—or can be autosomal
dominant, with variable penetrance and expression. The fact
that the dark choroid sign is present in approximately 85% of
patients with STGD157 suggests a pivotal role for genetic
analysis in the diagnosis of retinal dystrophies.
In conclusion, foveal sparing is a clinical phenomenon that
occurs primarily in patients with late-onset STGD1 and is
associated with the relative preservation of visual acuity,
although visual acuity ultimately deteriorates by the end stage
of the disease. Stargardt disease patients with foveal sparing
may be promising candidates for future therapeutic trials, as
delayed degeneration of the fovea increases the time window
for applying therapeutic interventions such as gene therapy.
Although the mechanisms that underlie foveal sparing are
currently unclear, expanding our knowledge of the metabolic
and biochemical processes that lead to foveal sparing can
facilitate the development of therapeutic strategies aimed at
preserving foveal function.
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